ReviewExtracellular Matrix

Tissue Inhibitors of Metalloproteinases in Cell Signaling: Metalloproteinase-Independent Biological Activities

See allHide authors and affiliations

Science Signaling  08 Jul 2008:
Vol. 1, Issue 27, pp. re6
DOI: 10.1126/scisignal.127re6


Over the past 20 years, the tissue inhibitors of metalloproteinases (TIMPs) have been implicated in direct regulation of cell growth and apoptosis. However, the mechanisms of these effects have been controversial. Recent work by several laboratories has identified specific signaling pathways and cell surface binding partners for members of the TIMP family. TIMP-2 binding to the integrin α3β1 is the first description of a cell surface receptor for a TIMP family member. TIMP-2 has been shown to induce gene expression, to promote G1 cell cycle arrest, and to inhibit cell migration. TIMP-1 binding to CD63 inhibits cell growth and apoptosis. These new findings suggest that TIMPs are multifunctional and can act either directly through cell surface receptors or indirectly through modulation of protease activity to direct cell fate. The emerging concept is that TIMPs function in a contextual fashion so that the mechanism of action depends on the tissue microenvironment.


As their name implies, tissue inhibitors of metalloproteinases (TIMPs) are endogenous inhibitors of metalloproteinase activities and, as such, were initially thought to function principally to modulate matrix metalloproteinase activity and to suppress extracellular matrix turnover. In 1989, Khokha et al. demonstrated that suppression of the endogenous tissue inhibitor of metalloproteinases (TIMP, now known as TIMP-1) with antisense RNA conferred an oncogenic phenotype in Swiss 3T3 cells (1). This was the first suggestion that TIMPs may present an intrinsic barrier to tumor progression. Subsequently, many laboratories observed that most human malignancies were associated with increased matrix metalloproteinase (MMP) activity and that TIMPs could modulate the invasive activity and metastatic capacity of tumor cells (25). These findings stimulated an effort for the development of synthetic MMP inhibitors as novel anticancer therapeutics (6). Although successful in a number of murine tumor models, these agents failed in human clinical trials (7). Retrospectively, it became apparent that the assumption that MMP activities were exclusively proinvasive and necessarily facilitated tumor progression was naïve. It is now widely recognized that MMPs, like many other extracellular matrix components, play a dual role in the process of tumor progression with both pro- and antitumorigenic activities (8).

This dual role extends to the TIMPs. Although originally characterized by their ability to inhibit MMP activity, TIMPs have additional biological activities that are just beginning to be recognized and characterized. Over the past 20 years, TIMPs have been shown to regulate a number of cellular processes including cell growth, migration, and apoptosis. Despite mounting evidence suggesting direct cell signaling capacity for the TIMPs, however, the requirement for MMP-inhibitory activity in mediating these cellular activities of the TIMPs remains controversial. Although TIMP-mediated inhibition of MMP activity is an important determinant of cell function, the concept of MMP-independent TIMP regulation of cell fate is now supported by the identification of specific cell-binding partners—and specific signaling events—for TIMP family members. This is particularly relevant to the cell signaling mechanisms mediated by TIMP-1 and TIMP-2. The recognition of these MMP-independent TIMP activities and understanding of the mechanisms involved have important implications for the development of new therapies for cancer and other chronic diseases.

The TIMP Gene Family

TIMPs have been identified in species ranging from Caenorhabditis elegans, to Drosophila, zebrafish, and humans; this suggests that they are ancient eukaryotic genes (911). Recent studies have shown developmental defects in TIMP-deficient organisms, in both nonmammalian and mammalian systems, revealing the importance of these proteins during embryonic development, as well as the possible functional redundancy of some TIMPs in mammalian development (1216). However, the study of TIMP function remains most closely associated with their role in tumor development and cancer progression.

The mammalian TIMP family has four members, which share substantial sequence homology and structural identity at the protein level. TIMPs have basically two structural domains: (i) an N-terminal domain consisting of six conserved cysteine residues forming three disulfide loops, which inhibits MMP activity, and (ii) a C-terminal domain that also contains six conserved cysteine residues and forms three disulfide loops (17). The overall structure of the N-terminal inhibitory domain is that of the wedge-shaped OB-fold (oligosaccharide/oligonucleotide–binding fold) that is found in DNA binding or oligosaccharide–binding proteins. This OB-fold is dominated by β-sheet structures separated by small flexible loop regions (17).

By definition, all members of the TIMP family inhibit MMP activity. This is accomplished through coordination of the Zn+2 of the MMP active site by the amino and carbonyl groups of the TIMP N-terminal cysteine residue. However, selective inhibition of some members of the MMP has been observed. For example, although TIMP-1 is the prototypic inhibitor for most MMP family members, it is a poor inhibitor of the membrane-type MMPs (MT-MMP) and MMP-19 (9, 18). TIMP-3 inhibits members of the ADAM (a disintegrin and metalloproteinase) family of proteases, although the mechanism for this inhibition appears to be distinct from that of MMP inhibition (11, 19). TIMP-2 is unique in that, in addition to inhibiting MMP activity, it selectively interacts with membrane type–1 (MT1)–MMP to facilitate the cell surface activation of pro–MMP-2 (9, 18, 20). Thus, TIMP-2 functions to both inhibit MMP activity and promote cell surface activation of pro–MMP-2 by MT1-MMP.

TIMP-3 specifically interacts with sulfated glycosaminoglycans and, as a result, is sequestered in the extracellular matrix (21), whereas the other TIMP family members remain soluble and diffusible. Although the biological relevance of the matrix association of TIMP-3 has not been determined, it suggests that TIMP-3’s pericellular distribution and availability for interactions with cell surface proteins may be more restricted than that of other members of the TIMP family. Many in vitro studies of TIMP-3 cellular functions have been conducted by addition of soluble, exogenous recombinant TIMP-3 and have not addressed the role of matrix binding, which is a unique feature of this inhibitor. By comparison, relatively few studies have focused on TIMP-4, so less is known about this member of the TIMP family.

TIMPs can be regulated at the transcriptional level by various cytokines and growth factors, resulting in tissue-specific, constitutive, or inducible expression (22). TIMP-1 is expressed in organs of reproduction, and TIMP-3 expression is found in the heart, kidney, and thymus. TIMP-4 shows the most selective pattern of tissue localization, as it is expressed predominately in heart and brain, as well as to a lesser degree in muscle and ovary (18, 23). Analysis of the TIMP promoters reveals that the TIMP-2 promoter contains several Sp1 sequences characteristic of housekeeping genes, a finding consistent with the constitutive pattern of TIMP-2 protein and mRNA expression observed in adult murine tissues (22, 24, 25).

Three members of the TIMP gene family are nested within the synapsin gene family (2628). The synapsin 1 gene nests TIMP-1, synapsin 2 nests TIMP-4, and synapsin 3 nests TIMP-3. TIMP-2 is the only member of the TIMP gene family that is not nested within a member of the synapsin family. Synapsins are a multigene family of phosphoproteins that are neuron-specific and are the most abundant protein of the synaptic vesicle (29). It has been proposed that they tether synaptic vesicles and regulate neurotransmitter release. The synapsin-TIMP gene nesting relationship began phylogenetically as far back as Drosophila, which suggests a strong linkage between these two gene families, although the implications of this association are not known (28).

TIMP-1 differs from the other members of the family in having a short exon 1 that is transcribed but not translated. The function of exon 1 appears related to the control of the specificity of tissue expression and may contain tissue-specific repressor elements (22, 30). TIMP-2 also has a distinct gene structure in that a nested gene, known as DDC8 (for differential display clone 8) (31), is present within the very large (~60 kb) first intron of the TIMP-2 gene (32). Furthermore, tissue extracts from the brain of the TIMP-2–deficient mouse contain TIMP-2 mRNA encoding exons 2 to 5 downstream of DDC8, which suggests alternative splicing between these two genes (31, 33). This would have important implications for delineating TIMP-2 functions associated with exons 2 to 5 in these mice.

MMP-Dependent TIMP Regulation of Cell Signaling

TIMP regulation of cell fate is a highly complex process whose interpretation is further complicated by the indirect effects of TIMP-mediated inhibition of MMP activity. Moreover, there are numerous conflicting reports of TIMP effects on the same cellular process. The complexities of understanding TIMP regulation of cell fate are highlighted here by focusing briefly on TIMP-1.

Recent studies have begun to identify signaling pathways involved in the MMP-dependent growth-promoting effects of TIMP-1. For instance, TIMP-1 specifically enhances the formation and growth of micrometastases in the liver (34). This effect is mediated through both the induction of hepatocyte growth factor (HGF) and the suppression of shedding its cognate receptor, cMet. It has been proposed, but not directly demonstrated, that the latter effect depends on inhibition of ADAM-10–mediated shedding of cMet. Thus, high TIMP-1 expression in the liver creates a microenvironment that is conducive to tumor dissemination and explains the observation that synthetic metalloproteinase inhibitors enhance formation of liver metastasis through inhibition of cMet shedding.

This research contrasts with reports that TIMP-1 inhibits MMP-mediated activation of HGF in the extracellular matrix and, consequently, reduces hepatocyte proliferation in a model of murine liver regeneration (35). Also, TIMP-1 inhibition of MMP-mediated degradation of insulin-like growth factor (IGF)–binding protein-3 (IGFBP-3) reduces bioavailability of IGF-II, which results in reduced growth of simian virus 40 (SV40) large T antigen–induced hepatocellular carcinoma (36).

These three studies emphasize the complexities of TIMP-associated cell signaling and the importance of recognizing that the observed effects of TIMPs on cell fate are highly dependent on the cellular context and details of the specific model system utilized.

TIMP Functions Independent of MMP Inhibition

TIMP promotion of cell growth

Sequencing of a TIMP-1 cDNA clone revealed its identity with a cloned protein demonstrating erythroid-potentiating activity (designated EPA) (37). EPA is a T lymphoblastic factor present in serum that supports the growth of erythroid precursors in vitro by a mechanism involving direct cell surface binding (38). TIMP-2 also has EPA (39). The maximal EPA observed in vitro was at TIMP-1 or -2 concentrations of 80 to 100 pM, much lower than their plasma concentration of 10 to 20 nM (40, 41). This suggests that TIMPs are unlikely to be critical regulatory factors for this activity.

Several laboratories have reported that TIMP-1 and TIMP-2 promote cell division, as measured by DNA content or [3H]thymidine uptake, in various epithelial (keratinocytes), mesenchymal (fibroblasts), and tumor cell lines (4247) (Table 1). TIMP-2 produced by the metanephric mesenchyme rescued ureteric bud epithelia from apoptosis and stimulated [3H]thymidine incorporation (25). These activities were not observed with use of synthetic MMP inhibitors. Collectively, these reports repeatedly demonstrated that this growth stimulation was observed with TIMP concentrations in the range of 10 to 50 nM, although some reports suggested higher concentrations were required. Moreover, these studies indicated that growth stimulation by TIMPs was independent of their inhibition of MMP activity, as shown through the use of reductive alkylation or sequence mutations, both of which disrupted TIMP MMP inhibitory activity but not growth stimulatory activity (45, 48). These studies also demonstrated the requirement for free TIMPs in stimulating cell division, in that the growth-promoting activity was abolished by complex formation with either pro- or active MMPs (45). Binding studies suggested the presence of high-affinity receptors, with Kd (dissociation constant) values reported in the low nanomolar range (<10 nM) by a number of laboratories (42, 49). These studies suggest that the effects of TIMPs on cell growth may be mediated by their direct binding to the cell surface—i.e., through a cell receptor mechanism.

Fig. 1.

Multiple pathways of TIMP-2–α3β1 signaling. (A) Paxillin (PAX) is a scaffolding protein associated with integrin receptors that is phosphorylated by activated Src. TIMP-2 binding to α3β1 activates C-terminal Src kinase (Csk), which inactivates Src, thus altering PAX phosphorylation. These changes in PAX phosphorylation mediated activation of the small GTPase Rap1 through a mechanism involving altered association of guanidine exchange factors (C3G and Crk) with PAX. Rap1 activation ultimately results in increased abundance of RECK, a cell surface–associated glycerol phosphate-inositol (GPI)–anchored metalloproteinase inhibitor. Enhanced RECK expression at both the mRNA and protein level is associated with inhibition of cell migration. This suggests that, in addition to inhibiting cellular proliferation, TIMP-2 also seems to promote expression of cellular differentiation markers, such as RECK. (B) Inhibition of receptor tyrosine kinase (RTK) growth factor activation. TIMP-2 binding to α3β1 integrin initiates RTK inactivation through the action of the protein tyrosine phosphatase Shp-1, which binds to SH2 sites created by phosphorylation of specific tyrosine residues. (C) Cell cycle arrest is mediated by the TIMP-2–induced de novo synthesis and nuclear translocation of p27Kip1, which down-regulates activity of cyclin-dependent kinases 4 and 2 (Cdk4/2). This results in hypophosphorylation of Rb protein and cell cycle arrest in G1.

Fig. 2.

Multiple pathways of TIMP-1–CD63 signaling. TIMP-1 and TIMP-4 interact with the tetraspanin CD63, which associates with the β1 subunit of integrin receptors. Downstream of CD63, TIMP-1 inhibits both the intrinsic and extrinsic cell death pathways through activation of the FAK-PI3K pathway. These effects are mediated by activation of the extracellular signal–regulated kinase (ERK). In addition, TIMP-1 inhibits cell growth through a mechanism similar to that of TIMP-2, involving suppression of cyclin D1 and up-regulation of p27Kip1. The net effect is hypophosphorylation of Rb protein and cell cycle arrest in the G1 phase of the cell cycle.

Table 1.

Metalloproteinase-independent biological activity of TIMPs.

Several distinct signaling pathways have been implicated in TIMP growth-promoting activity, including the mitogen-activated protein kinase (MAPK) pathway and cyclic adenosine 3′,5′-monophosphate (cAMP)–protein kinase A (PKA) pathway (43, 50). The growth-promoting activities of TIMP-1 and TIMP-2 may require activation of Ras, albeit by distinct pathways, which suggests independent receptor mechanisms (51). Collectively, these studies demonstrate that the functions of TIMPs are contextual; for instance, growth-promoting activity was only observed in the presence of free TIMPs, independent of MMP-binding or MMP inhibition.

TIMP-3 accelerates the morphological changes associated with cell transformation and stimulates the proliferation of growth-retarded, nontransformed cells under low serum conditions (52). These findings suggest that TIMP-3 may promote the development of the transformed phenotype in cultured cells. It is not clear if this is an MMP-independent effect of TIMP-3 mediated by a cell autonomous mechanism.

TIMP antiapoptotic activity

TIMP-1 expression inversely correlates with the susceptibility to induction of programmed cell death (apoptosis) in various human Burkitt’s lymphoma cell lines (53) (Table 1). These studies demonstrated that treatment with recombinant TIMP-1 (1.4 to 140 nM) or forced expression of TIMP-1 in a TIMP-negative cell line reduces susceptibility to induction of apoptosis (intrinsic and extrinsic pathways), suppresses caspase-3 activity, and sustains DNA synthesis up to 5 days under serum-free culture conditions. TIMP-1–neutralizing antibodies block these effects, which suggests an autocrine mechanism. This antiapoptotic effect is not observed with TIMP-2 or the synthetic MMP inhibitor BB-94, but is retained after reduction and alkylation of TIMP-1, which demonstrates that the mechanism is independent of MMP inhibition. Furthermore, TIMP-1 suppression of apoptosis correlates with increased abundance of Bcl-XL and IκBα (inhibitor of nuclear factor κBα) protein, but not Bcl-2 or NF-κB (nuclear factor κB), which suggests that these effects are mediated by a specific antiapoptotic signaling pathway. Subsequently, it was observed that TIMP-1 enhances expression of survival and differentiation cytokines, such as interleukin-10 (IL-10), that also contribute to the antiapoptotic effect (54). These findings are consistent with an apparent growth stimulatory activity of TIMP-1, in that the survival factor activity prevents cell loss and allows the continued unstimulated cell growth to dominate because of the exponential nature of cell proliferation.

In vivo, forced expression of TIMP-1 in Burkitt’s lymphoma xenografts results in a biphasic effect on tumor growth, with initial enhancement and subsequent suppression of tumor growth (55). Tumor regression is associated with a failure of these tumors to develop an angiogenic response and TIMP-1 inhibition of endothelial cell migration (55).

TIMP-1 also inhibits apoptosis and anoikis (apoptosis induced by loss of cell adhesion) in human breast epithelial cells in vitro (56). Here, Bcl-2 overexpression increased the abundance of TIMP-1 protein in breast epithelial cell lines (MCF10A and MCF7), whereas it has no effect on MMP or TIMP-2 expression. Furthermore, TIMP-1 overexpression suppresses anoikis in MCF10A cells. These findings show that the antiapoptotic activity of TIMP-1 does not depend on its ability to stabilize cell-matrix interactions and is independent of MMP inhibition. In this model system, TIMP-1 activates the focal adhesion kinase (FAK)–phosphoinositol-3 kinase (PI3K) pathway to protect cells from intrinsic and extrinsic cell death (5658). These studies indicate that TIMP-1 mediates activation of specific signal transduction pathways that protect cells from apoptosis in a fashion that is independent of its metalloproteinase inhibitory activity.

The antiapoptotic activity of TIMP-1 is not restricted to tumor cells. Expression of TIMP-1, but not that of TIMP-2, prevents cytokine-mediated apoptosis and cytokine-mediated glucose-stimulated insulin secretion in rat pancreatic islets (59). These effects are mediated by TIMP-1 inhibition of cytokine activation of NF-κB, which suggests a similar mechanism to those reported for malignant cells. TIMP-1 produced by embryonic stem cells implanted for the treatment of myocardial infarction inhibits apoptosis in cardiomyocytes (60). These data suggest that the effects of TIMP-1 on programmed cell death may be mediated by cell-specific pathways and that these pathways may not differ greatly between normal and malignant cell compartments.

Unlike the relatively well-established antiapoptotic effects of TIMP-1 discussed, the effect of TIMP-2 on programmed cell death has not been well characterized, with only two conflicting reports in the literature and no clearly defined signaling pathway (61, 62). TIMP-3 promotes apoptosis in several in vitro systems, including vascular smooth muscle cells (63) and various tumor cell lines (64, 65). Recent findings in TIMP-3–null mice suggest that TIMP-3 can either promote or inhibit apoptosis depending on the model system examined (15, 6668). In either case, there is little or no data to support the concept that TIMP-3 initiates cell signaling directly to mediate effects on apoptosis. Instead, TIMP-3 functions indirectly by modulating metalloproteinase activity (of MMPs or ADAMs or both) to alter cell fate.

The fourth member of the TIMP family, TIMP-4, has been reported to stimulate tumorigenesis of human breast cancer cells in nude mice (69) (Table 1). Consistent with this stimulation of tumorigenesis, TIMP-4 increases the abundance of Bcl-2 and Bcl-XL protein. TIMP-4 also inhibits apoptosis in human breast cancer cells in vitro and mammary tumors in vivo. A synthetic MMP inhibitor, BB-94, did not have such an antiapoptotic effect, which suggests that TIMP-4, like TIMP-1, can promote tumor growth by inhibiting apoptosis. Thus, the signaling pathways and receptor mechanism for the antiapoptotic effect of these two TIMPs may be similar.

TIMP growth-inhibitory activity

In addition to the numerous reports describing TIMP-1 and TIMP-2 growth-stimulating activity, there are reports documenting growth-inhibitory activity for these TIMP family members (Table 1). Again, this suggests that the specific effects of the TIMPs on cell fate depend on the cell context and specific model system under study. For example, in TIMP-1–deficient mice, there is an increase in mammary epithelial proliferation resulting in increased ductal branching and expansion of the ductal structures, which is reversed by introduction of exogenous TIMP-1 in slow-release pellets (70). Also, transgenic mice expressing autoactivating MMP in the mammary epithelial show enhanced apoptosis and depletion of entactin levels from the basement membrane, but these phenotypic changes can be rescued by crossbreeding with TIMP-1 transgenic mice (69). Although these effects were initially attributed to inhibition of MMP activity, specifically that of MMP-3, recent findings suggest that TIMP-1 may arrest mammary cell proliferation directly. A recent report shows that TIMP-1 induces cell cycle arrest in G1 in association with down-regulation of cyclin D1, up-regulation of the cyclin-dependent kinase inhibitor p27Kip1, and hypophosphorylation of the retinoblastoma (Rb) protein (71). These data suggest that TIMP-1 mediates a cell signaling pathway that results in altered gene expression and inhibition of cell growth. Although arrested in G1 phase of the cell cycle, the TIMP-1 overexpressing cells remain viable and do not show detectable levels of apoptosis, consistent with the antiapoptotic effect of TIMP-1 described above.

A novel antiangiogenic agent from bovine cartilage, the cartilage-derived inhibitor (CDI) of angiogenesis, was isolated and characterized in 1990 (72). CDI copurifies with MMP-inhibitor activity and inhibits angiogenesis in vivo and in vitro. The N-terminal amino acid sequence of CDI shows close identity with TIMP-2, suggesting that CDI is TIMP-related (72). Analysis of the angio-inhibitory effects of TIMP-1 and TIMP-2 indicated that TIMP-2, but not TIMP-1 or the synthetic MMP inhibitor BB-94, inhibits the fibroblast growth factor 2 (FGF-2)–stimulated proliferation of human endothelial cells (73). This inhibitory effect is not observed with a pro–MMP-2–TIMP-2 complex, which suggests that only free TIMP-2 inhibits endothelial cell growth in response to FGF-2 stimulation. These studies indicate that TIMP-2 selectively inhibits the growth of endothelial cells through an MMP-independent mechanism; however, the signaling mechanism was not identified.

As described previously, TIMP-3 modulates apoptosis through its regulation of metalloproteinase activity. A direct inhibition of cell growth has not been definitively demonstrated, although a recent report suggests TIMP-3 may act additively with other cellular components to inhibit endothelial cell growth (vide infra) (74, 75) (Table 1). Electroporation-mediated intramuscular injection of TIMP-4 expression plasmid results in a sustained increase in plasma TIMP-4 concentration, which inhibits the growth of G401 Wilms tumor xenografts and is associated with cellular internalization of the exogenous TIMP-4; however, a signaling mechanism or cellular receptor mediating these effects has not been described (76) (Table 1).

Uncoupling TIMP-Mediated Growth Inhibition from MMP Inhibition

Appending a single amino acid, alanine, to the amino terminus of TIMP-2 to produce Ala+TIMP-2 yields a TIMP-2 mutant devoid of MMP-inhibitory activity (77). Ala+TIMP-2 does not inhibit MMP-2 or MT1-MMP activity or mediate MT1-MMP activation of pro–MMP-2 (77, 78).

Both TIMP-2 and Ala+TIMP-2 bind to the surface of human A549 lung cancer cells with very high affinity (Kd = 147 pM), and there is no competition for binding by the synthetic MMP inhibitor BB94 or TIMP-1 (78). Furthermore, the binding of Ala+TIMP-2 shows only partial competition by MT1-MMP–blocking antibodies, and colocalization studies demonstrate that TIMP-2 and Ala+TIMP-2 binding is, at least in part, independent of MT1-MMP. These findings have been confirmed by research showing two distinct cell surface binding sites for TIMP-2 (79). Furthermore, cell surface binding of TIMP-2 is independent of the level of MT1-MMP expression (80), and not all cell surface–bound TIMP-2 can be replaced by synthetic MMP inhibitors in competition experiments (79).

Studies using Ala+TIMP-2 showed that TIMP-2–mediated growth suppression in vitro is independent of MMP inhibition (78) and demonstrated that TIMP-2 or Ala+TIMP-2 growth suppression is mediated by reduced tyrosine kinase growth factor receptor phosphorylation and activation. These changes correlate with an increase in the protein tyrosine phosphatase activity of Shp-1 (78).

More recent research has definitively demonstrated uncoupling of the MMP-inhibitory and antiangiogenic activities of TIMP-2 (81). TIMP-2 inhibits endothelial cell proliferation via a mechanism involving the C-terminal domain of TIMP-2, specifically at the C-terminal disulfide loop, referred to as loop 6 (81). This region is encoded by exon 5 of the TIMP-2 gene, and as noted above, TIMP-2–deficient mice may produce alternative splice variants of the DDC8 gene that could express proteins containing a TIMP-2 loop 6 structure, which might retain antiangiogenic activity (31).

Establishing a New Paradigm: Identification of TIMP Receptors

TIMP-2 binding to the endothelial cell surface and its ability to inhibit endothelial cell proliferation are independent of MMP inhibition, as demonstrated by Ala+TIMP-2 (82). The binding of TIMP-2 to the human microvascular endothelial cell surface is saturable and reversible with Kd = 900 pM. Competition binding studies demonstrated that TIMP-2 binding to the surface of human microvascular endothelial cells can be competed by antibodies that block the integrin subunits β1 and α3. The interaction of TIMP-2 with α3β1 cell surface integrin was confirmed by coimmunoprecipitation of α3β1 integrin, with TIMP-2–specific antibodies, and by loss of TIMP-2 growth suppressive activity in β1-null fibroblasts. This was the first demonstration of TIMP interaction with a specific cell surface protein and identified this integrin as a TIMP-2 receptor.

Subsequent studies demonstrated that TIMP-2 or Ala+TIMP-2 binding through α3β1 integrin results in G1 growth arrest and enhanced de novo expression of the cyclin-dependent kinase inhibitor p27Kip1 (83). Further studies revealed that TIMP-2 and Ala+TIMP-2 enhance the expression of the reversion-enhancing, cysteine-rich protein with Kazal motifs, also known as RECK (84). RECK is a membrane-associated inhibitor of MMPs (MMP-2, MMP-9, MT1-MMP), as well as of ADAM-10 (85), and enhanced RECK expression is associated with inhibition of endothelial cell migration (84). TIMP-2 induction of RECK expression is mediated by inhibition of the activity of the Src tyrosine kinase, resulting in an altered pattern of phosphorylation of the adaptor protein paxillin at residues 31 and 118 (86). This altered phosphorylation results in inactivation of the small guanosine triphosphatase (GTPase) Rac1 and a reciprocal activation of the small GTPase Rap1, resulting in loss of a migratory phenotype. Collectively, these findings suggest that TIMP-2 inhibits angiogenesis by inducing endothelial cell differentiation to a quiescent state with G1 cell cycle arrest, enhanced expression of RECK, and inhibition of cell migration, through a specific cell-signaling paradigm (Fig. 1).

A recent report suggests that TIMP-2 binding to MT1-MMP can stimulate MCF7 breast cancer cell growth through activation of the MAPK pathway (87). This study showed that TIMP-2 and Ala+TIMP-2 bind to MT1-MMP and that both elicit MAPK activation. Because Ala+TIMP-2 does not bind to the catalytic site of MT1-MMP, the authors proposed that the observed growth effect is mediated by TIMP-2 binding to other sites on MT1-MMP, possibly the hemopexin or hinge domain. Additional studies are needed to assess the contribution of this reported mechanism to tumor growth in vivo.

Identification of α3β1 integrin as the first TIMP-signaling receptor stimulated the search for additional binding partners for other TIMP proteins. As previously noted, the high-affinity cell surface binding of TIMP-1 to myeloid leukemia cells and keratinocytes suggested the presence of cellular binding partners (38, 42, 88). Recently, a yeast two-hybrid approach was used to identify CD63, a member of the tetraspanin family, as a cell-binding partner for TIMP-1 in MCF10A human mammary epithelial cells (89). Confocal microscopy confirmed colocalization of TIMP-1 with CD63 and the β1 integrin subunit. TIMP-1 overexpression disrupted acinar formation in three-dimensional Matrigel cultures and inhibited MCF10A apoptosis, as previously described. Down-regulation of CD63 with short hairpin RNA resulted in reduced TIMP-1 binding and restored acinar formation, cell polarization, and cell apoptosis. Furthermore, independent investigations have demonstrated that CD63 regulates PI3K, FAK, Src, and Akt signaling pathways that have been implicated in the antiapoptotic activity of TIMP-1 (90). These investigators have also reported that CD63 interacts with TIMP-4, but not with TIMP-2 or TIMP-3 (91). As described above, TIMP-1 and TIMP-4 have both been reported to have proapoptotic functions; thus, it is not surprising to find that they probably share cell surface receptors. Thus, TIMP-1 (and probably TIMP-4) also uses a not previously described signaling paradigm that is initiated by binding to CD63 (Fig. 2).

TIMP-3 also inhibits angiogenesis (92). Mutations in the TIMP-3 gene are associated with Sorsby fundus dystrophy, a macular degenerative disease characterized by submacular neovascularization that occurs in the third and fourth decades of age. A recent report demonstrated that TIMP-3 bound to the vascular endothelial growth factor receptor–2, a principal receptor driving endothelial cell proliferation and that this binding inhibited vascular endothelial growth factor VEGF-A binding; thus, TIMP-3 acts as a VEGF-A antagonist (75). This activity is completely independent of inhibition of MMP activity, as demonstrated by the use of a TIMP-3 mutant, as well as the lack of an effect of TIMP-2 or synthetic MMP inhibitors. The median inhibitory concentration (IC50) for inhibition of VEGF binding to the VEGF receptor VEGFR-2 was 3.3 to 4.5 μg/ml, which is about 10 times the IC50 for inhibition of endothelial cell proliferation and migration (IC50 = 0.3 to 3.0 μg/ml). Although this difference may be attributable to differences in the sensitivity of the read-out of these assays, as the authors suggest, it is also possible that TIMP-3 inhibition of angiogenesis involves a dual mechanism. In either case, the 3.3 to 4.5 μg/ml TIMP-3 concentrations are very high compared with physiologic concentration of other TIMPs, and because TIMP-3 is matrix bound, it is difficult to assess the physiologic importance of these findings.

TIMP-3 may also interact with angiotensin II type 2 receptor to additively inhibit angiogenesis (74). This interaction was also identified with yeast two-hybrid screening. In the presence of both factors, VEGF-induced growth of endothelial cells was additively inhibited, and the activation of Akt and endothelial nitric oxide synthetase phosphorylation were blocked; unfortunately, little detail about the involvement of specific signaling pathways is available at this early phase of investigation.

TIMP Tissue Distribution: Clues to Functions?

A recent study using quantitative polymerase chain reaction demonstrated essentially ubiquitous and abundant expression of all four mammalian TIMPs in most mouse tissues (23). TIMP-2 was constitutively expressed in high abundance in all tissues of the adult mouse, with the expression of the other three TIMPs demonstrating more selective patterns of tissue distribution, as described above. Although TIMP concentrations may be substantial in some normal tissues, the expression of active MMP species in these normal tissues is usually very low or nonexistent (23). TIMP-2 abundance is decreased in human cancers both through genetic polymorphisms associated with increased cancer risk and through epigenetic mechanisms involving hypermethylation of the TIMP-2 promoter (9398). In addition, the increase in MMP active sites in the tumor microenvironment may further reduce the effective concentration of free TIMP-2 (not bound in a complex) (99, 100). Thus, the function of TIMP-2 is entirely dependent on the cellular context in which it is present.

The recent demonstration that TIMP-2 inhibits growth and promotes neurite differentiation in vitro via an α3β1 integrin–dependent mechanism is consistent with this hypothesis (101). In this system, cell cycle arrest also occurs in G1 but appears to be mediated by enhanced expression of the cyclin-dependent kinase inhibitor p21Cip, not p27Kip1, as in the endothelial cell system. Furthermore, TIMP-2 expression correlates with the appearance of microfilament-positive neurons, and live cell-labeling experiments showed TIMP-2 association only with α3 integrin–positive cells (102). These observations suggest that up-regulation of TIMP-2 expression by proliferative stimuli implicates TIMP-2 expression in the transition from neuronal proliferation to promotion of terminal neuronal differentiation. This concept is further supported by the subsequent demonstration that TIMP-2 knockout mice have motor deficits, and these motor deficits are the first demonstration of a significant phenotype for the TIMP-2–deficient mice (12).

In a similar fashion, it has been proposed that TIMP-1 function is also influenced by cellular context, specifically, in that MMPs, in particular MMP-9, may reduce the effective concentration of TIMP-1 and may compete with TIMP-1 for binding to the cell surface receptor CD63 (91). In contrast to TIMP-2, TIMP-1 concentrations are increased in cancer patients, particularly in those with breast or colorectal carcinoma, and this increase is negatively associated with patient outcome (103107). These recent studies have demonstrated the clinical utility of TIMP-1 as a biomarker and independent prognostic factor in breast, colorectal, and several hematological cancers. They are consistent with the antiapoptotic activity of TIMP-1 mediated by CD63 binding.

The identification of cell surface receptors for TIMP family members is a first step in beginning to sort out the MMP-independent, cytokine-like functions of the TIMPs. It is to be hoped that this can serve as a starting point for the molecular dissection of signaling events associated with the various activities of these proteins and their function in both normal physiologic and pathologic processes. It is clear that the pleiotropic activities of the TIMP family members are complex and depend on subtle interactions with other extracellular components, as well as direct interactions with cell-binding partners. Understanding these processes and how they are modulated during disease progression will be helpful in development of novel therapeutic interventions.


  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.
  32. 32.
  33. 33.
  34. 34.
  35. 35.
  36. 36.
  37. 37.
  38. 38.
  39. 39.
  40. 40.
  41. 41.
  42. 42.
  43. 43.
  44. 44.
  45. 45.
  46. 46.
  47. 47.
  48. 48.
  49. 49.
  50. 50.
  51. 51.
  52. 52.
  53. 53.
  54. 54.
  55. 55.
  56. 56.
  57. 57.
  58. 58.
  59. 59.
  60. 60.
  61. 61.
  62. 62.
  63. 63.
  64. 64.
  65. 65.
  66. 66.
  67. 67.
  68. 68.
  69. 69.
  70. 70.
  71. 71.
  72. 72.
  73. 73.
  74. 74.
  75. 75.
  76. 76.
  77. 77.
  78. 78.
  79. 79.
  80. 80.
  81. 81.
  82. 82.
  83. 83.
  84. 84.
  85. 85.
  86. 86.
  87. 87.
  88. 88.
  89. 89.
  90. 90.
  91. 91.
  92. 92.
  93. 93.
  94. 94.
  95. 95.
  96. 96.
  97. 97.
  98. 98.
  99. 99.
  100. 100.
  101. 101.
  102. 102.
  103. 103.
  104. 104.
  105. 105.
  106. 106.
  107. 107.
View Abstract

Stay Connected to Science Signaling

Navigate This Article